Aripiprazole, brexpiprazole, and cariprazine constitute the DRPA (dopamine receptor partial agonists) subcategory of second-generation antipsychotics. Seemingly, they appear to be similar.
However, they differ significantly in their pharmacodynamics, pharmacokinetics, drug interactions, efficacy, safety and tolerability, approved indications, dosing, formulations, and other factors related their use.